Transcriptomics

Dataset Information

0

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE165052 | GEO | 2021/06/16

REPOSITORIES: GEO

Json Xml

Similar Datasets

Unknown Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
| S-EPMC8271218 | biostudies-literature
Genomics Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development
| PRJNA693039 | ENA
Unknown Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
| S-EPMC6882350 | biostudies-literature
Unknown PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
| S-EPMC5854713 | biostudies-literature
Unknown Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
| S-EPMC8770599 | biostudies-literature
Unknown The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
| S-EPMC6801076 | biostudies-literature
Unknown Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
| S-EPMC5522225 | biostudies-literature
Unknown Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
| S-EPMC4967013 | biostudies-literature
Unknown Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
| S-EPMC6916751 | biostudies-literature
Unknown PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
| S-EPMC8395221 | biostudies-literature